Platforms for Aerosol Drug Delivery: Ensuring Therapeutic Success
Newman SP.
RDD Asia 2014. Volume , 2014: 1-12.
Abstract:
A wide range of inhaler technologies is available to companies developing novel inhaled drug products. Correct choice of inhaler platform (inhaler device plus formulation) is critical to the success of the drug delivery program. The chosen platform must meet the requirements of patients, healthcare professionals, regulators, and funders of healthcare. Platform selection needs to take into account the type of drug being delivered, the likely dose, and the type of patient who will be using the inhaler system. Pressurized metered dose inhalers (pMDIs) and dry powder inhalers (DPIs) and some next generation technologies are ideal for delivering low drug doses used to treat patients with asthma and chronic obstructive pulmonary disease (COPD). Other inhaled therapies including biopharmaceuticals may require inhaler systems capable of delivering markedly larger doses, and with greater efficiency and precision. Whatever platform is chosen, it is essential that patients understand the need to use an inhaler system correctly, and to adhere to the treatment regimen.
I have a subscription
Log in for instant access.
I do not have a subscription
Purchase Article (in PDF format)
